Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Deborah Collyar: What's In It for Patients?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement

Mar

04

Today In Oncology

Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes

CD123-Targeting ADC Shows Activity in AML and BPDCN

Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds

Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence

Research Suggests AI Pathology Models May Take Unreliable Shortcuts to Identify Cancer Biomarkers

Advertisement

© 2026 HSP News Service, L.L.C.